Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia [0.03%]
赞鲁布替尼与伊布替尼治疗慢性淋巴细胞白血病的费用-效果分析及人数计算模型研究
Asher Chanan-Khan,Kirollos Hanna,Mei Xue et al.
Asher Chanan-Khan et al.
Background: Zanubrutinib, a Bruton tyrosine kinase inhibitor, is an approved treatment for chronic lymphocytic leukemia (CLL). Objective: ...
Assessing variation in US payer coverage of anti-vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema [0.03%]
评估美国各支付方针对血管内皮生长因子疗法治疗年龄相关性黄斑变性、糖尿病视网膜病变和糖尿病黄斑水肿的报销差异
James D Chambers,Molly T Beinfeld,Terry Richardson et al.
James D Chambers et al.
Background: Timely anti-vascular endothelial growth factor (anti-VEGF) therapy is recommended to preserve vision in age-related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Cove...
Catherine M Lockhart,Mark R Barakat,Jeffrey D Dunn et al.
Catherine M Lockhart et al.
In September 2024, AMCP and Impact Education, LLC, held a virtual Market Insights summit with chief medical and pharmacy officers and other senior health care executives to discuss the management of retinal diseases in patients with diabete...
Out-of-pocket costs for direct oral anticoagulants and prescription abandonment among patients with nonvalvular atrial fibrillation or venous thromboembolism [0.03%]
非瓣膜性房颤或静脉血栓栓塞症患者直接口服抗凝药的自费费用及处方遗弃现象
Maryia Zhdanava,Veronica Ashton,Jill Korsiak et al.
Maryia Zhdanava et al.
Background: Direct oral anticoagulants (DOACs) are used to prevent thrombosis in patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE). Despite their clinical benefits, some patients abando...
Bruce W Sherman,Brian Sils,Kimberly Westrich
Bruce W Sherman
As a major provider of health insurance for working-age Americans, employers can play a significant role in improving the health equity of their employees and family members. In this commentary, we describe how different stakeholders, inclu...
Association between statin discontinuation after proprotein convertase subtilisin/kexin type 9 inhibitor initiation and subsequent atherosclerotic cardiovascular disease events [0.03%]
启动前蛋白转化酶枯草溶菌素/黄 Abbott 裂解酶类型9抑制剂后停用他汀类药物与随后的动脉粥样硬化心血管疾病事件之间的关联
Samuel K Peasah,Tiffany Lee,Duy Do et al.
Samuel K Peasah et al.
Background: Clinical guidelines recommend the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) in patients with atherosclerotic cardiovascular disease (ASCVD) and nonoptimal low-density lipoprotei...
Frequency of first generic drugs approved through "skinny labeling," 2021 to 2023 [0.03%]
2021至2023年通过"瘦身标签"获批的首仿药频率
Therese J Ziaks,Chukwubuikem M Akanegbu,Alexander C Egilman et al.
Therese J Ziaks et al.
Background: Brand-name drug manufacturers receive a market exclusivity period following US Food and Drug Administration (FDA) approval, which can be extended through obtaining additional patents such as method-of-use pate...
Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective [0.03%]
Sotagliflozin对心力衰竭和2型糖尿病患者经济影响分析：从美国付款人的角度进行预算影响分析
Jason Shafrin,Shanshan Wang,Jaehong Kim et al.
Jason Shafrin et al.
Background: Heart failure (HF) is a leading cause of mortality in the United States, often complicated by comorbidities like diabetes mellitus. These patients face high hospitalization risks, impacting clinical outcomes a...
Yuvraj Pathak,Elvira Makk Frid,Nico Gabriel et al.
Yuvraj Pathak et al.
Since 2021, hospitals have been required to report the prices of common, shoppable services, including drugs, as per the Hospital Price Transparency Rule. In this paper, we used Hospital Price Transparency data aggregated by Turquoise Healt...
The effectiveness and value of tabelecleucel for the treatment of Epstein-Barr virus-positive posttransplant lymphoproliferative disease [0.03%]
Tabelecleucel治疗EB病毒阳性移植后淋巴增殖性疾病的有效性和价值
Avery McKenna,Grace A Lin,Woojung Lee et al.
Avery McKenna et al.